| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle, Smooth, Vascular | 69 | 2022 | 1493 | 9.030 |
Why?
|
| Vasoconstriction | 52 | 2022 | 592 | 8.060 |
Why?
|
| Matrix Metalloproteinases | 18 | 2021 | 392 | 6.760 |
Why?
|
| Vasodilation | 38 | 2021 | 961 | 6.640 |
Why?
|
| Uterus | 17 | 2024 | 649 | 4.150 |
Why?
|
| Matrix Metalloproteinase 2 | 13 | 2022 | 459 | 3.980 |
Why?
|
| Endothelium, Vascular | 37 | 2019 | 4432 | 3.940 |
Why?
|
| Matrix Metalloproteinase 9 | 12 | 2024 | 632 | 3.730 |
Why?
|
| Pre-Eclampsia | 19 | 2022 | 1230 | 3.670 |
Why?
|
| Hypertension, Pregnancy-Induced | 10 | 2024 | 518 | 3.570 |
Why?
|
| Placenta | 20 | 2024 | 1708 | 3.480 |
Why?
|
| Varicose Veins | 13 | 2020 | 155 | 3.460 |
Why?
|
| Vascular Diseases | 11 | 2022 | 1161 | 3.080 |
Why?
|
| Nitric Oxide | 31 | 2021 | 2133 | 3.040 |
Why?
|
| Hypertension | 38 | 2023 | 8539 | 2.990 |
Why?
|
| Uterine Artery | 4 | 2024 | 30 | 2.900 |
Why?
|
| Muscle Contraction | 26 | 2021 | 1197 | 2.770 |
Why?
|
| Vena Cava, Inferior | 11 | 2020 | 459 | 2.720 |
Why?
|
| Rats, Sprague-Dawley | 57 | 2024 | 8166 | 2.580 |
Why?
|
| Vasoconstrictor Agents | 30 | 2023 | 654 | 2.530 |
Why?
|
| Pregnancy, Animal | 11 | 2014 | 124 | 2.480 |
Why?
|
| Protein Kinase C | 24 | 2016 | 1202 | 2.450 |
Why?
|
| ADAM Proteins | 5 | 2022 | 237 | 2.390 |
Why?
|
| Calcium | 40 | 2016 | 5726 | 2.290 |
Why?
|
| Phenylephrine | 33 | 2016 | 293 | 2.060 |
Why?
|
| Cyclic GMP | 15 | 2017 | 395 | 2.030 |
Why?
|
| Estrogens | 13 | 2023 | 1521 | 1.990 |
Why?
|
| Pregnancy Complications, Cardiovascular | 11 | 2016 | 515 | 1.960 |
Why?
|
| Ischemia | 12 | 2024 | 1876 | 1.940 |
Why?
|
| Uterine Contraction | 4 | 2022 | 91 | 1.890 |
Why?
|
| Rats | 64 | 2024 | 23729 | 1.820 |
Why?
|
| Receptor, Endothelin B | 5 | 2014 | 46 | 1.810 |
Why?
|
| Calcium Signaling | 11 | 2018 | 733 | 1.810 |
Why?
|
| Blood Pressure | 32 | 2024 | 8485 | 1.680 |
Why?
|
| Disintegrins | 3 | 2022 | 27 | 1.670 |
Why?
|
| Biological Factors | 3 | 2023 | 157 | 1.650 |
Why?
|
| Progesterone | 10 | 2022 | 742 | 1.620 |
Why?
|
| Hypertension, Pulmonary | 6 | 2022 | 1580 | 1.490 |
Why?
|
| Receptors, Estrogen | 11 | 2013 | 2208 | 1.470 |
Why?
|
| Estrogen Receptor beta | 5 | 2015 | 168 | 1.450 |
Why?
|
| Blood Vessels | 9 | 2017 | 1113 | 1.420 |
Why?
|
| Caveolin 1 | 4 | 2015 | 255 | 1.410 |
Why?
|
| Aorta | 21 | 2017 | 2042 | 1.400 |
Why?
|
| Gonadal Steroid Hormones | 8 | 2010 | 701 | 1.380 |
Why?
|
| Estrogen Replacement Therapy | 6 | 2013 | 1208 | 1.380 |
Why?
|
| Pregnancy | 56 | 2024 | 29858 | 1.370 |
Why?
|
| Neovascularization, Physiologic | 5 | 2021 | 1344 | 1.320 |
Why?
|
| Animals | 140 | 2024 | 168388 | 1.310 |
Why?
|
| Mesenteric Arteries | 5 | 2021 | 178 | 1.270 |
Why?
|
| Glycosaminoglycans | 3 | 2024 | 607 | 1.270 |
Why?
|
| Angiotensin II | 10 | 2023 | 849 | 1.170 |
Why?
|
| Microvessels | 4 | 2022 | 575 | 1.170 |
Why?
|
| Estrogen Receptor alpha | 5 | 2015 | 581 | 1.140 |
Why?
|
| Myometrium | 3 | 2022 | 174 | 1.140 |
Why?
|
| Potassium Chloride | 16 | 2013 | 230 | 1.120 |
Why?
|
| Pulmonary Artery | 6 | 2022 | 1938 | 1.110 |
Why?
|
| Venous Insufficiency | 3 | 2024 | 110 | 1.110 |
Why?
|
| Endothelin-1 | 7 | 2013 | 302 | 1.060 |
Why?
|
| Placental Circulation | 4 | 2021 | 37 | 1.050 |
Why?
|
| Estradiol | 12 | 2013 | 1937 | 1.050 |
Why?
|
| Myocytes, Smooth Muscle | 6 | 2022 | 698 | 1.020 |
Why?
|
| NG-Nitroarginine Methyl Ester | 16 | 2015 | 260 | 1.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 4 | 2018 | 557 | 1.010 |
Why?
|
| Thrombospondins | 3 | 2022 | 193 | 1.000 |
Why?
|
| Nitric Oxide Synthase | 10 | 2015 | 906 | 1.000 |
Why?
|
| Adaptation, Physiological | 5 | 2016 | 1301 | 0.990 |
Why?
|
| Signal Transduction | 29 | 2020 | 23427 | 0.970 |
Why?
|
| Vasomotor System | 3 | 2016 | 207 | 0.960 |
Why?
|
| Vasodilator Agents | 14 | 2013 | 973 | 0.910 |
Why?
|
| Angiotensin I | 1 | 2023 | 56 | 0.910 |
Why?
|
| Sodium Chloride, Dietary | 6 | 2011 | 293 | 0.880 |
Why?
|
| Biological Phenomena | 1 | 2023 | 28 | 0.870 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2017 | 151 | 0.850 |
Why?
|
| Enzyme Induction | 3 | 2013 | 451 | 0.820 |
Why?
|
| Nitric Oxide Synthase Type III | 6 | 2013 | 704 | 0.820 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2024 | 145 | 0.790 |
Why?
|
| Menopause | 6 | 2012 | 1646 | 0.770 |
Why?
|
| Sodium, Dietary | 3 | 2015 | 425 | 0.760 |
Why?
|
| Aortic Aneurysm, Abdominal | 3 | 2020 | 1230 | 0.740 |
Why?
|
| Veins | 4 | 2015 | 768 | 0.740 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2021 | 4355 | 0.740 |
Why?
|
| Placentation | 2 | 2020 | 78 | 0.730 |
Why?
|
| Endothelins | 8 | 2014 | 127 | 0.730 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2021 | 91 | 0.730 |
Why?
|
| Receptor, Endothelin A | 3 | 2014 | 56 | 0.680 |
Why?
|
| Receptors, Endothelin | 3 | 2011 | 56 | 0.640 |
Why?
|
| Enzyme Inhibitors | 20 | 2015 | 3710 | 0.630 |
Why?
|
| Receptors, Mineralocorticoid | 3 | 2015 | 163 | 0.630 |
Why?
|
| Acetylcholine | 11 | 2012 | 628 | 0.600 |
Why?
|
| Arteries | 5 | 2015 | 1125 | 0.600 |
Why?
|
| Sodium Chloride | 4 | 2006 | 587 | 0.600 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2018 | 57 | 0.590 |
Why?
|
| Epoprostenol | 4 | 2012 | 246 | 0.580 |
Why?
|
| Disease | 3 | 2017 | 672 | 0.570 |
Why?
|
| Muscle Relaxation | 4 | 2012 | 138 | 0.570 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2021 | 1170 | 0.570 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 3 | 2017 | 97 | 0.570 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2017 | 60 | 0.570 |
Why?
|
| Isoenzymes | 9 | 2005 | 1688 | 0.550 |
Why?
|
| Receptor, Angiotensin, Type 2 | 2 | 2023 | 60 | 0.550 |
Why?
|
| Coronary Vasospasm | 5 | 2004 | 81 | 0.540 |
Why?
|
| Organ Specificity | 3 | 2017 | 1967 | 0.530 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 278 | 0.530 |
Why?
|
| Calcium Channel Blockers | 7 | 2016 | 694 | 0.530 |
Why?
|
| Female | 84 | 2024 | 392485 | 0.530 |
Why?
|
| Enzyme Assays | 1 | 2017 | 104 | 0.520 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2021 | 499 | 0.520 |
Why?
|
| Collagen | 3 | 2022 | 2638 | 0.510 |
Why?
|
| HELLP Syndrome | 1 | 2015 | 40 | 0.510 |
Why?
|
| Vascular Resistance | 6 | 2013 | 932 | 0.500 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 212 | 0.490 |
Why?
|
| Calmodulin-Binding Proteins | 2 | 2015 | 232 | 0.490 |
Why?
|
| Isometric Contraction | 7 | 2013 | 150 | 0.480 |
Why?
|
| Receptor, Angiotensin, Type 1 | 5 | 2023 | 153 | 0.480 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2019 | 10764 | 0.480 |
Why?
|
| Testosterone | 9 | 2023 | 2472 | 0.470 |
Why?
|
| Phytoestrogens | 2 | 2012 | 59 | 0.470 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2017 | 1745 | 0.470 |
Why?
|
| Intracellular Membranes | 3 | 2002 | 389 | 0.460 |
Why?
|
| Blood Circulation | 1 | 2015 | 249 | 0.460 |
Why?
|
| Renal Artery | 3 | 2015 | 351 | 0.460 |
Why?
|
| Sex Characteristics | 6 | 2023 | 2637 | 0.460 |
Why?
|
| Litter Size | 3 | 2021 | 49 | 0.450 |
Why?
|
| Collagen Type I | 1 | 2017 | 616 | 0.450 |
Why?
|
| Extracellular Matrix | 7 | 2020 | 1726 | 0.450 |
Why?
|
| Pancreatic Elastase | 2 | 2004 | 128 | 0.440 |
Why?
|
| Peptide Fragments | 3 | 2023 | 5114 | 0.440 |
Why?
|
| Disease Models, Animal | 12 | 2020 | 18234 | 0.440 |
Why?
|
| Placental Insufficiency | 2 | 2004 | 50 | 0.440 |
Why?
|
| Protease Inhibitors | 3 | 2012 | 753 | 0.440 |
Why?
|
| Mesenteric Veins | 1 | 2013 | 86 | 0.430 |
Why?
|
| Receptors, Epoprostenol | 1 | 2012 | 12 | 0.420 |
Why?
|
| Coronary Vessels | 7 | 2004 | 3094 | 0.410 |
Why?
|
| Plant Preparations | 1 | 2013 | 94 | 0.410 |
Why?
|
| Protein Kinase C-epsilon | 3 | 2007 | 43 | 0.410 |
Why?
|
| Up-Regulation | 5 | 2017 | 4120 | 0.410 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2021 | 3489 | 0.410 |
Why?
|
| Cardiovascular Diseases | 8 | 2017 | 15499 | 0.410 |
Why?
|
| Gene Expression Regulation | 4 | 2020 | 11900 | 0.400 |
Why?
|
| Acidosis, Respiratory | 1 | 2012 | 38 | 0.400 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2015 | 1249 | 0.400 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 36 | 0.390 |
Why?
|
| Electrophysiological Phenomena | 1 | 2014 | 307 | 0.390 |
Why?
|
| Venous Pressure | 2 | 2008 | 57 | 0.390 |
Why?
|
| Escin | 1 | 2011 | 2 | 0.390 |
Why?
|
| RNA Interference | 1 | 2020 | 2832 | 0.380 |
Why?
|
| Blotting, Western | 8 | 2015 | 5034 | 0.380 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2011 | 110 | 0.370 |
Why?
|
| Down-Regulation | 5 | 2020 | 2913 | 0.360 |
Why?
|
| Airway Remodeling | 1 | 2012 | 133 | 0.360 |
Why?
|
| Pressoreceptors | 1 | 2010 | 99 | 0.360 |
Why?
|
| Dinoprost | 5 | 2003 | 138 | 0.350 |
Why?
|
| Substrate Specificity | 4 | 2017 | 1793 | 0.350 |
Why?
|
| Thorax | 1 | 2013 | 555 | 0.350 |
Why?
|
| Oxytocin | 3 | 2022 | 402 | 0.340 |
Why?
|
| Humans | 74 | 2024 | 761326 | 0.340 |
Why?
|
| Aorta, Thoracic | 8 | 2015 | 1097 | 0.340 |
Why?
|
| Cardiovascular System | 2 | 2015 | 835 | 0.330 |
Why?
|
| Renal Circulation | 2 | 2009 | 291 | 0.320 |
Why?
|
| Lower Extremity | 1 | 2017 | 1201 | 0.320 |
Why?
|
| Muscles | 1 | 2014 | 1575 | 0.320 |
Why?
|
| Male | 57 | 2024 | 360621 | 0.320 |
Why?
|
| Proteinuria | 2 | 2022 | 607 | 0.310 |
Why?
|
| Drug Design | 1 | 2014 | 1050 | 0.310 |
Why?
|
| Leukocyte Rolling | 1 | 2008 | 69 | 0.310 |
Why?
|
| Splanchnic Circulation | 1 | 2008 | 119 | 0.300 |
Why?
|
| Membrane Potentials | 6 | 2011 | 1089 | 0.300 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2008 | 132 | 0.300 |
Why?
|
| Developing Countries | 1 | 2020 | 2887 | 0.300 |
Why?
|
| Mesentery | 1 | 2008 | 202 | 0.300 |
Why?
|
| Enzyme Activation | 11 | 2007 | 3592 | 0.290 |
Why?
|
| Potassium Channel Blockers | 3 | 2015 | 161 | 0.280 |
Why?
|
| Abdomen | 1 | 2013 | 1128 | 0.280 |
Why?
|
| Protein Kinase C-alpha | 1 | 2007 | 113 | 0.280 |
Why?
|
| Nitroprusside | 5 | 2012 | 272 | 0.280 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 617 | 0.280 |
Why?
|
| Tissue Distribution | 5 | 2017 | 2265 | 0.280 |
Why?
|
| Cardiovascular Agents | 1 | 2013 | 840 | 0.270 |
Why?
|
| Calcium, Dietary | 1 | 2009 | 529 | 0.270 |
Why?
|
| Culture Techniques | 5 | 2004 | 531 | 0.260 |
Why?
|
| Gamma Rays | 1 | 2007 | 318 | 0.260 |
Why?
|
| Organ Culture Techniques | 2 | 2019 | 794 | 0.260 |
Why?
|
| Microcirculation | 2 | 2008 | 1269 | 0.260 |
Why?
|
| Eclampsia | 1 | 2006 | 56 | 0.260 |
Why?
|
| Nitrites | 4 | 2013 | 159 | 0.260 |
Why?
|
| Interleukin-6 | 3 | 2024 | 3210 | 0.260 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2010 | 529 | 0.250 |
Why?
|
| Calmodulin | 1 | 2006 | 218 | 0.250 |
Why?
|
| Cytokines | 4 | 2022 | 7390 | 0.250 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2006 | 109 | 0.240 |
Why?
|
| Hyperglycemia | 1 | 2013 | 1375 | 0.240 |
Why?
|
| Endothelial Cells | 5 | 2011 | 3543 | 0.240 |
Why?
|
| Rats, Inbred SHR | 5 | 2003 | 186 | 0.240 |
Why?
|
| Estrus | 2 | 2014 | 70 | 0.240 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 1135 | 0.240 |
Why?
|
| Swine | 10 | 2004 | 5915 | 0.230 |
Why?
|
| Hemodynamics | 2 | 2017 | 4167 | 0.230 |
Why?
|
| Kidney | 4 | 2009 | 7049 | 0.230 |
Why?
|
| Diltiazem | 3 | 2016 | 131 | 0.230 |
Why?
|
| MicroRNAs | 1 | 2020 | 3796 | 0.230 |
Why?
|
| Potassium Channels | 1 | 2007 | 537 | 0.230 |
Why?
|
| Cyclins | 1 | 2006 | 594 | 0.230 |
Why?
|
| Placenta Diseases | 1 | 2006 | 199 | 0.220 |
Why?
|
| Dilatation, Pathologic | 3 | 2013 | 527 | 0.220 |
Why?
|
| Calcium Channels | 3 | 2009 | 620 | 0.220 |
Why?
|
| Fetal Growth Retardation | 2 | 2018 | 580 | 0.220 |
Why?
|
| Aging | 3 | 2009 | 8704 | 0.220 |
Why?
|
| Cadherins | 1 | 2008 | 904 | 0.220 |
Why?
|
| Anticoagulants | 1 | 2019 | 4813 | 0.220 |
Why?
|
| Osmolar Concentration | 5 | 2012 | 661 | 0.210 |
Why?
|
| Extracellular Space | 2 | 2002 | 563 | 0.210 |
Why?
|
| Cerebrovascular Circulation | 1 | 2013 | 2727 | 0.210 |
Why?
|
| Cells, Cultured | 8 | 2024 | 18962 | 0.210 |
Why?
|
| Metalloproteases | 1 | 2022 | 61 | 0.210 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2013 | 1555 | 0.200 |
Why?
|
| Ferrets | 5 | 1995 | 177 | 0.200 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 4414 | 0.200 |
Why?
|
| Tissue Culture Techniques | 2 | 2017 | 290 | 0.200 |
Why?
|
| Receptors, Oxytocin | 1 | 2022 | 69 | 0.200 |
Why?
|
| Aldosterone | 3 | 2011 | 866 | 0.200 |
Why?
|
| Guanylate Cyclase | 2 | 2013 | 205 | 0.190 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2024 | 691 | 0.190 |
Why?
|
| Fura-2 | 5 | 2001 | 107 | 0.190 |
Why?
|
| RNA, Messenger | 5 | 2022 | 12787 | 0.190 |
Why?
|
| Monocrotaline | 2 | 2012 | 26 | 0.190 |
Why?
|
| Adrenergic alpha-Agonists | 4 | 2004 | 177 | 0.190 |
Why?
|
| Oligopeptides | 3 | 2014 | 1186 | 0.190 |
Why?
|
| Nitrates | 3 | 2013 | 263 | 0.180 |
Why?
|
| Eicosanoids | 2 | 2002 | 282 | 0.180 |
Why?
|
| Connexins | 1 | 2022 | 352 | 0.180 |
Why?
|
| Receptors, Adrenergic, alpha | 3 | 2010 | 146 | 0.180 |
Why?
|
| Apoptosis | 3 | 2021 | 9474 | 0.180 |
Why?
|
| Antihypertensive Agents | 2 | 2012 | 2023 | 0.180 |
Why?
|
| Maleimides | 2 | 2016 | 113 | 0.180 |
Why?
|
| Thrombophlebitis | 2 | 2013 | 289 | 0.170 |
Why?
|
| Scleroderma, Localized | 2 | 2013 | 87 | 0.170 |
Why?
|
| Reactive Oxygen Species | 3 | 2016 | 2137 | 0.170 |
Why?
|
| Muscle Tonus | 3 | 2012 | 82 | 0.170 |
Why?
|
| Leukocytes | 1 | 2008 | 2029 | 0.170 |
Why?
|
| Regional Blood Flow | 2 | 2019 | 1495 | 0.170 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2002 | 292 | 0.170 |
Why?
|
| Sodium | 2 | 2002 | 1588 | 0.170 |
Why?
|
| Models, Animal | 4 | 2010 | 2112 | 0.170 |
Why?
|
| Mice, Knockout | 5 | 2015 | 14409 | 0.170 |
Why?
|
| Catheter Ablation | 1 | 2013 | 2752 | 0.170 |
Why?
|
| Oxytocics | 1 | 2000 | 67 | 0.170 |
Why?
|
| Phosphorylation | 5 | 2016 | 8312 | 0.170 |
Why?
|
| Aorta, Abdominal | 2 | 2017 | 626 | 0.170 |
Why?
|
| Oxidative Stress | 3 | 2009 | 3108 | 0.170 |
Why?
|
| Collagen Type IV | 1 | 2019 | 126 | 0.160 |
Why?
|
| Spironolactone | 2 | 2015 | 411 | 0.160 |
Why?
|
| Phenols | 2 | 2015 | 517 | 0.160 |
Why?
|
| Hindlimb | 1 | 2021 | 512 | 0.160 |
Why?
|
| Oxadiazoles | 3 | 2004 | 94 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2015 | 7852 | 0.150 |
Why?
|
| Animals, Newborn | 2 | 2019 | 2678 | 0.150 |
Why?
|
| Trophoblasts | 1 | 2019 | 224 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2009 | 2093 | 0.150 |
Why?
|
| Immunoblotting | 4 | 2008 | 1647 | 0.150 |
Why?
|
| Risk Factors | 10 | 2020 | 74152 | 0.150 |
Why?
|
| Cell Cycle | 1 | 2006 | 2930 | 0.150 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2011 | 361 | 0.150 |
Why?
|
| Fertility | 1 | 2022 | 771 | 0.150 |
Why?
|
| Lipoproteins, LDL | 1 | 2001 | 642 | 0.150 |
Why?
|
| Receptors, Progesterone | 1 | 2022 | 1129 | 0.150 |
Why?
|
| Gelatinases | 1 | 2017 | 88 | 0.140 |
Why?
|
| Enzyme Activators | 1 | 2017 | 57 | 0.140 |
Why?
|
| Saphenous Vein | 4 | 2024 | 518 | 0.140 |
Why?
|
| Enzyme Precursors | 1 | 2017 | 174 | 0.140 |
Why?
|
| Cysteine | 1 | 2022 | 892 | 0.140 |
Why?
|
| Ion Transport | 3 | 2003 | 319 | 0.140 |
Why?
|
| Rats, Inbred WKY | 4 | 2001 | 151 | 0.140 |
Why?
|
| Hyperhomocysteinemia | 1 | 2017 | 118 | 0.140 |
Why?
|
| Phorbol 12,13-Dibutyrate | 3 | 2001 | 41 | 0.140 |
Why?
|
| rho-Associated Kinases | 2 | 2009 | 281 | 0.140 |
Why?
|
| Amino Acid Motifs | 1 | 2019 | 931 | 0.130 |
Why?
|
| Quinoxalines | 3 | 2004 | 296 | 0.130 |
Why?
|
| Gestational Age | 2 | 2017 | 3576 | 0.130 |
Why?
|
| Mice | 8 | 2020 | 81474 | 0.130 |
Why?
|
| Sex Factors | 6 | 2010 | 10551 | 0.130 |
Why?
|
| Myosin Light Chains | 1 | 2016 | 121 | 0.130 |
Why?
|
| Endopeptidases | 1 | 2020 | 773 | 0.130 |
Why?
|
| Tetraethylammonium | 1 | 2015 | 55 | 0.130 |
Why?
|
| Peripheral Arterial Disease | 2 | 2017 | 1272 | 0.130 |
Why?
|
| Lung | 2 | 2012 | 9994 | 0.130 |
Why?
|
| Dimerization | 1 | 2017 | 891 | 0.130 |
Why?
|
| Birth Weight | 2 | 2019 | 2100 | 0.130 |
Why?
|
| Renin-Angiotensin System | 2 | 2015 | 737 | 0.120 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2017 | 280 | 0.120 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 656 | 0.120 |
Why?
|
| Verapamil | 3 | 2004 | 242 | 0.120 |
Why?
|
| Nitriles | 2 | 2010 | 971 | 0.120 |
Why?
|
| Protein Transport | 3 | 2007 | 1967 | 0.120 |
Why?
|
| Maternal Health Services | 1 | 2020 | 461 | 0.120 |
Why?
|
| Angiogenic Proteins | 1 | 2015 | 101 | 0.120 |
Why?
|
| Viper Venoms | 1 | 2014 | 15 | 0.120 |
Why?
|
| Tetradecanoylphorbol Acetate | 4 | 2004 | 818 | 0.120 |
Why?
|
| Chronic Disease | 3 | 2024 | 9319 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 4567 | 0.110 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 11070 | 0.110 |
Why?
|
| Labor, Obstetric | 1 | 2017 | 323 | 0.110 |
Why?
|
| Carotid Arteries | 2 | 2015 | 941 | 0.110 |
Why?
|
| Heart Injuries | 1 | 2015 | 206 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 1791 | 0.110 |
Why?
|
| Mitogens | 1 | 1993 | 230 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2009 | 476 | 0.110 |
Why?
|
| Coronary Circulation | 1 | 1999 | 1565 | 0.110 |
Why?
|
| Hydrostatic Pressure | 1 | 2013 | 98 | 0.100 |
Why?
|
| Thromboxane-A Synthase | 1 | 2012 | 34 | 0.100 |
Why?
|
| Caffeine | 3 | 2003 | 700 | 0.100 |
Why?
|
| Leg | 1 | 2017 | 1089 | 0.100 |
Why?
|
| Plants, Medicinal | 1 | 2013 | 165 | 0.100 |
Why?
|
| Pyrazoles | 2 | 2015 | 2007 | 0.100 |
Why?
|
| Reference Values | 3 | 2008 | 4921 | 0.100 |
Why?
|
| Protein Isoforms | 2 | 2011 | 1698 | 0.100 |
Why?
|
| Indoles | 2 | 2016 | 1832 | 0.100 |
Why?
|
| Ammonium Chloride | 1 | 2012 | 72 | 0.100 |
Why?
|
| Prostaglandins I | 1 | 2011 | 13 | 0.100 |
Why?
|
| Age Factors | 3 | 2020 | 18401 | 0.100 |
Why?
|
| Potassium | 3 | 1993 | 1311 | 0.100 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2012 | 105 | 0.100 |
Why?
|
| Peptides, Cyclic | 1 | 2014 | 392 | 0.100 |
Why?
|
| Cholinergic Agonists | 1 | 2012 | 75 | 0.100 |
Why?
|
| Protein Multimerization | 1 | 2017 | 983 | 0.100 |
Why?
|
| Fetal Development | 1 | 2017 | 769 | 0.100 |
Why?
|
| Nucleic Acid Conformation | 1 | 2015 | 901 | 0.100 |
Why?
|
| Tyrosine | 2 | 1996 | 1438 | 0.100 |
Why?
|
| Diosmin | 1 | 2011 | 6 | 0.100 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2011 | 18 | 0.100 |
Why?
|
| Norepinephrine | 3 | 1990 | 897 | 0.100 |
Why?
|
| Muscle, Smooth | 2 | 1992 | 926 | 0.100 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 318 | 0.090 |
Why?
|
| Echinomycin | 1 | 2010 | 2 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2011 | 43 | 0.090 |
Why?
|
| Myography | 1 | 2012 | 111 | 0.090 |
Why?
|
| Sapogenins | 1 | 2010 | 2 | 0.090 |
Why?
|
| Naphthalenes | 2 | 2004 | 198 | 0.090 |
Why?
|
| Probability | 2 | 2008 | 2478 | 0.090 |
Why?
|
| Dermatitis | 1 | 2013 | 201 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2013 | 296 | 0.090 |
Why?
|
| Ginsenosides | 1 | 2010 | 12 | 0.090 |
Why?
|
| Butadienes | 1 | 2010 | 107 | 0.090 |
Why?
|
| Integrins | 1 | 2015 | 834 | 0.090 |
Why?
|
| Physical Stimulation | 1 | 2012 | 518 | 0.090 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2021 | 1642 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 598 | 0.090 |
Why?
|
| Benzoquinones | 1 | 2010 | 198 | 0.090 |
Why?
|
| Subcellular Fractions | 2 | 2001 | 532 | 0.090 |
Why?
|
| Gene Expression | 2 | 2021 | 7582 | 0.090 |
Why?
|
| Hypertrophy | 1 | 2012 | 559 | 0.090 |
Why?
|
| Receptors, Angiotensin | 1 | 2010 | 141 | 0.090 |
Why?
|
| Progestins | 1 | 2012 | 301 | 0.090 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2012 | 412 | 0.090 |
Why?
|
| Hematologic Diseases | 1 | 2014 | 496 | 0.080 |
Why?
|
| Estrogen Antagonists | 1 | 2010 | 150 | 0.080 |
Why?
|
| Catalytic Domain | 1 | 2012 | 705 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2012 | 10203 | 0.080 |
Why?
|
| Molecular Sequence Data | 3 | 2012 | 17640 | 0.080 |
Why?
|
| Inflammation | 1 | 2009 | 10760 | 0.080 |
Why?
|
| Renin | 1 | 2011 | 639 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1996 | 2423 | 0.080 |
Why?
|
| Cell Separation | 3 | 2001 | 1722 | 0.080 |
Why?
|
| Lactams, Macrocyclic | 1 | 2010 | 318 | 0.080 |
Why?
|
| Genomic Imprinting | 1 | 2010 | 330 | 0.080 |
Why?
|
| Histone Demethylases | 1 | 2011 | 320 | 0.080 |
Why?
|
| Cytosol | 2 | 2007 | 888 | 0.080 |
Why?
|
| Biopsy | 1 | 2020 | 6768 | 0.080 |
Why?
|
| Orchiectomy | 2 | 2001 | 463 | 0.070 |
Why?
|
| Ovariectomy | 2 | 2001 | 614 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 472 | 0.070 |
Why?
|
| Carbon Dioxide | 1 | 2012 | 1146 | 0.070 |
Why?
|
| Cromakalim | 1 | 2007 | 22 | 0.070 |
Why?
|
| Rabbits | 5 | 2011 | 4779 | 0.070 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2007 | 43 | 0.070 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2007 | 20 | 0.070 |
Why?
|
| Losartan | 1 | 2009 | 265 | 0.070 |
Why?
|
| Phenotype | 2 | 2017 | 16603 | 0.070 |
Why?
|
| Ethinyl Estradiol | 1 | 2007 | 113 | 0.070 |
Why?
|
| Time Factors | 6 | 2010 | 39974 | 0.070 |
Why?
|
| Ankle Brachial Index | 2 | 2017 | 163 | 0.070 |
Why?
|
| Organ Size | 1 | 2012 | 2252 | 0.070 |
Why?
|
| Sympathetic Fibers, Postganglionic | 1 | 2006 | 14 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 2453 | 0.070 |
Why?
|
| Indomethacin | 1 | 2007 | 326 | 0.070 |
Why?
|
| NAD | 1 | 2010 | 614 | 0.070 |
Why?
|
| Protein Kinases | 1 | 1993 | 1607 | 0.070 |
Why?
|
| Cytoskeleton | 2 | 2007 | 1170 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2022 | 10431 | 0.070 |
Why?
|
| Feedback, Physiological | 1 | 2008 | 476 | 0.070 |
Why?
|
| Lymphokines | 1 | 2009 | 927 | 0.070 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2009 | 389 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 431 | 0.070 |
Why?
|
| Synovial Membrane | 1 | 2009 | 532 | 0.070 |
Why?
|
| Prosthesis Design | 1 | 2013 | 2115 | 0.060 |
Why?
|
| Aneurysm | 1 | 2009 | 337 | 0.060 |
Why?
|
| Metformin | 1 | 2013 | 907 | 0.060 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2007 | 276 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 3 | 1995 | 2468 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2013 | 1974 | 0.060 |
Why?
|
| Guinea Pigs | 1 | 2007 | 1317 | 0.060 |
Why?
|
| Piperidines | 1 | 2014 | 1657 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 882 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 6525 | 0.060 |
Why?
|
| Portal Vein | 3 | 1992 | 431 | 0.060 |
Why?
|
| Ligands | 1 | 2012 | 3271 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2015 | 5439 | 0.060 |
Why?
|
| Equipment Design | 1 | 2013 | 3510 | 0.060 |
Why?
|
| Water-Electrolyte Balance | 1 | 2006 | 325 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 4286 | 0.060 |
Why?
|
| Vasculitis | 1 | 2009 | 522 | 0.060 |
Why?
|
| Capillary Permeability | 1 | 2008 | 774 | 0.060 |
Why?
|
| Coronary Restenosis | 1 | 2007 | 396 | 0.060 |
Why?
|
| Heart Valve Prosthesis | 1 | 2013 | 1469 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 15262 | 0.060 |
Why?
|
| Immune System | 1 | 2009 | 794 | 0.060 |
Why?
|
| Atherosclerosis | 2 | 2012 | 3413 | 0.060 |
Why?
|
| Random Allocation | 1 | 2008 | 2389 | 0.060 |
Why?
|
| Intracellular Fluid | 1 | 2003 | 201 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2014 | 1909 | 0.060 |
Why?
|
| Constriction | 1 | 2003 | 171 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 2947 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2024 | 64645 | 0.050 |
Why?
|
| Blood Coagulation | 1 | 2009 | 1154 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 3076 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 6392 | 0.050 |
Why?
|
| Calcium Channel Agonists | 1 | 2002 | 26 | 0.050 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2002 | 34 | 0.050 |
Why?
|
| Stress, Mechanical | 2 | 2016 | 1674 | 0.050 |
Why?
|
| Calcium Radioisotopes | 1 | 2002 | 9 | 0.050 |
Why?
|
| Imidazoles | 1 | 2009 | 1179 | 0.050 |
Why?
|
| Phorbol Esters | 2 | 2001 | 108 | 0.050 |
Why?
|
| Kidney Medulla | 1 | 2002 | 169 | 0.050 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2002 | 89 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 2273 | 0.050 |
Why?
|
| Stimulation, Chemical | 2 | 1999 | 306 | 0.050 |
Why?
|
| Lipid Peroxides | 1 | 2001 | 74 | 0.050 |
Why?
|
| Wound Healing | 1 | 2013 | 2802 | 0.050 |
Why?
|
| Natriuresis | 1 | 2001 | 105 | 0.050 |
Why?
|
| China | 2 | 2017 | 2348 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 14665 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 3082 | 0.050 |
Why?
|
| Base Sequence | 1 | 2012 | 12449 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 13446 | 0.050 |
Why?
|
| Cell Movement | 1 | 2013 | 5202 | 0.050 |
Why?
|
| Hypertension, Renal | 1 | 2001 | 135 | 0.050 |
Why?
|
| Isotonic Solutions | 1 | 2001 | 117 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 5665 | 0.050 |
Why?
|
| Models, Biological | 1 | 2017 | 9468 | 0.040 |
Why?
|
| Culture Media | 1 | 2002 | 899 | 0.040 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 2 | 1991 | 56 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2024 | 673 | 0.040 |
Why?
|
| Castration | 1 | 2000 | 151 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2009 | 2418 | 0.040 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2001 | 213 | 0.040 |
Why?
|
| Monocytes | 1 | 2009 | 2573 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2012 | 3816 | 0.040 |
Why?
|
| Methylene Blue | 1 | 2000 | 155 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 1626 | 0.040 |
Why?
|
| Carbazoles | 1 | 2001 | 220 | 0.040 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 1998 | 65 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2001 | 338 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 2217 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 2853 | 0.040 |
Why?
|
| Biological Transport | 2 | 1994 | 2090 | 0.040 |
Why?
|
| Staurosporine | 1 | 1999 | 242 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2009 | 2481 | 0.040 |
Why?
|
| Isoquinolines | 2 | 1991 | 352 | 0.040 |
Why?
|
| Postmenopause | 1 | 2007 | 2513 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2003 | 881 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2004 | 1597 | 0.040 |
Why?
|
| Carcinogens | 1 | 2000 | 451 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2001 | 540 | 0.040 |
Why?
|
| Diet | 2 | 2008 | 8074 | 0.040 |
Why?
|
| Obesity | 1 | 1999 | 12934 | 0.040 |
Why?
|
| Perfusion | 1 | 2002 | 1374 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2017 | 22124 | 0.040 |
Why?
|
| Arginine | 1 | 2001 | 933 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 2870 | 0.040 |
Why?
|
| Body Weight | 1 | 2008 | 4614 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 1246 | 0.030 |
Why?
|
| Pyridines | 1 | 2009 | 2870 | 0.030 |
Why?
|
| Genotype | 1 | 2011 | 12982 | 0.030 |
Why?
|
| Myocardium | 1 | 2009 | 4723 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2003 | 1078 | 0.030 |
Why?
|
| Serotonin | 1 | 2001 | 1041 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2004 | 4013 | 0.030 |
Why?
|
| Vitamin D | 1 | 2009 | 3304 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2024 | 1886 | 0.030 |
Why?
|
| Peptides | 1 | 2007 | 4342 | 0.030 |
Why?
|
| Middle Aged | 5 | 2024 | 220774 | 0.030 |
Why?
|
| Differential Threshold | 1 | 1994 | 80 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 489 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 1995 | 455 | 0.030 |
Why?
|
| Homocysteine | 1 | 2017 | 638 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 1996 | 8997 | 0.030 |
Why?
|
| Mitochondria | 1 | 2007 | 3624 | 0.030 |
Why?
|
| Hypertonic Solutions | 1 | 1993 | 82 | 0.030 |
Why?
|
| Mammals | 1 | 1998 | 1132 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2001 | 1901 | 0.030 |
Why?
|
| Logistic Models | 2 | 2017 | 13251 | 0.030 |
Why?
|
| Adult | 2 | 2024 | 221122 | 0.020 |
Why?
|
| Sarcolemma | 1 | 1991 | 65 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2012 | 26211 | 0.020 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2011 | 18 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 1991 | 384 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 3419 | 0.020 |
Why?
|
| Aged | 4 | 2024 | 169179 | 0.020 |
Why?
|
| Prevalence | 2 | 2017 | 15719 | 0.020 |
Why?
|
| Microscopy | 1 | 1995 | 902 | 0.020 |
Why?
|
| Piperazines | 2 | 1991 | 2519 | 0.020 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1987 | 163 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 17872 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2017 | 9639 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 12059 | 0.010 |
Why?
|
| Rats, Inbred Dahl | 1 | 2002 | 34 | 0.010 |
Why?
|
| Ion Channels | 1 | 1987 | 1040 | 0.010 |
Why?
|
| Guanidines | 1 | 2002 | 192 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2011 | 4280 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2002 | 512 | 0.010 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 2 | 1990 | 86 | 0.010 |
Why?
|
| Thionucleotides | 2 | 1990 | 112 | 0.010 |
Why?
|
| Guanosine Triphosphate | 2 | 1990 | 316 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 13635 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1987 | 2820 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2017 | 23981 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2002 | 2176 | 0.010 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 1992 | 100 | 0.010 |
Why?
|
| Heart Rate | 1 | 2002 | 4197 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 1990 | 169 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 1990 | 287 | 0.010 |
Why?
|
| Buffers | 1 | 1989 | 146 | 0.010 |
Why?
|
| Methods | 1 | 1989 | 1074 | 0.000 |
Why?
|
| Cell Division | 1 | 1996 | 4466 | 0.000 |
Why?
|
| Permeability | 1 | 1989 | 722 | 0.000 |
Why?
|
| GTP-Binding Proteins | 1 | 1989 | 950 | 0.000 |
Why?
|